Bill

Bill > HB820


VA HB820

VA HB820
Sickle cell disease; annual review of medication and treatment, report.


summary

Introduced
01/09/2024
In Committee
02/22/2024
Crossed Over
01/30/2024
Passed
02/29/2024
Dead
Signed/Enacted/Adopted
04/02/2024

Introduced Session

2024 Regular Session

Bill Summary

Department of Medical Assistance Services; annual review of medication and treatment for sickle cell disease; report. Directs the Department of Medical Assistance Services to conduct an annual review of all medications and forms of treatment for sickle cell disease, and services for enrollees with a diagnosis of sickle cell disease, that are eligible for coverage under the state plan for medical assistance services. The bill requires the Department to report its findings and recommendations by November 15 each year to the Chairmen of the House Committee on Health and Human Services and the Senate Committee on Education and Health and to the Joint Commission on Health Care. Department of Medical Assistance Services; annual review of medication and treatment for sickle cell disease; report. Directs the Department of Medical Assistance Services to conduct an annual review of all medications and forms of treatment for sickle cell disease, and services for enrollees with a diagnosis of sickle cell disease, that are eligible for coverage under the state plan for medical assistance services. The bill requires the Department to report its findings and recommendations by November 15 each year to the Chairmen of the House Committee on Health and Human Services and the Senate Committee on Education and Health and to the Joint Commission on Health Care.

AI Summary

This bill directs the Department of Medical Assistance Services (DMAS) to conduct an annual review of all medications, services, and forms of treatment for sickle cell disease that are eligible for coverage under the state's Medicaid program. The purpose of the review is to determine if the available covered options are adequate to meet the needs of enrollees with sickle cell disease and whether DMAS should seek to expand coverage. DMAS is required to solicit and consider input from the public, particularly those with knowledge and experience in sickle cell disease treatment. The bill also mandates that DMAS submit a report by November 15th each year detailing the findings from the review and any recommendations to the relevant legislative committees and the Joint Commission on Health Care.

Committee Categories

Health and Social Services

Sponsors (10)

Last Action

Governor: Acts of Assembly Chapter text (CHAP0306) (on 04/02/2024)

bill text


bill summary

Loading...

bill summary

Loading...
Loading...